DAMASSI, ALESSANDRA
 Distribuzione geografica
Continente #
EU - Europa 1.020
AS - Asia 207
NA - Nord America 138
SA - Sud America 14
AF - Africa 1
Totale 1.380
Nazione #
IT - Italia 982
US - Stati Uniti d'America 131
SG - Singapore 89
VN - Vietnam 48
CN - Cina 43
FR - Francia 12
BD - Bangladesh 8
BR - Brasile 8
HK - Hong Kong 6
CA - Canada 5
FI - Finlandia 5
JP - Giappone 4
AT - Austria 3
GB - Regno Unito 3
IN - India 3
CO - Colombia 2
DE - Germania 2
ES - Italia 2
IE - Irlanda 2
IQ - Iraq 2
MX - Messico 2
UA - Ucraina 2
AL - Albania 1
AR - Argentina 1
CH - Svizzera 1
CL - Cile 1
DK - Danimarca 1
EC - Ecuador 1
HU - Ungheria 1
ID - Indonesia 1
KR - Corea 1
MD - Moldavia 1
PH - Filippine 1
RO - Romania 1
SI - Slovenia 1
TH - Thailandia 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 1.380
Città #
Genoa 619
Rapallo 133
Genova 111
Vado Ligure 106
Singapore 45
Ashburn 30
San Jose 17
Ho Chi Minh City 14
Council Bluffs 12
Beijing 11
Lauterbourg 11
Da Nang 7
Hanoi 7
Hong Kong 5
Santa Clara 5
Boardman 4
Bordighera 4
Helsinki 4
São Paulo 4
Capurso 3
Haiphong 3
Orem 3
Vienna 3
Dallas 2
Dublin 2
Frankfurt am Main 2
Kyiv 2
Los Angeles 2
New York 2
Newark 2
Tokyo 2
Toronto 2
Basra 1
Bedsted Thy 1
Biên Hòa 1
Brampton 1
Brooklyn 1
Brugherio 1
Budapest 1
Bueno Brandão 1
Buffalo 1
Bình Phước 1
Canindé de São Francisco 1
Cape Coral 1
Caracas 1
Cardiff 1
Chennai 1
Chicago 1
Chisinau 1
City of London 1
Delhi 1
Detroit 1
Dezhou 1
Edison 1
Elizabeth 1
Englewood 1
Folsom 1
Fresno 1
Guadalupe 1
Guangzhou 1
Guarulhos 1
Helena 1
Houston 1
Huechuraba 1
Hải Dương 1
Iola 1
Iztapalapa 1
Kansas City 1
Kapurthala Town 1
Khon Kaen 1
Kitchener 1
Lake Odessa 1
Lanús 1
Lappeenranta 1
Lavras 1
Lewes 1
Ljubljana 1
London 1
Long Xuyen 1
Madrid 1
Marseille 1
Maumelle 1
Midland 1
Montreal 1
Nha Trang 1
Oklahoma City 1
Park River 1
Pasto 1
Phoenix 1
Phủ Lý 1
Plano 1
Quận Bình Thạnh 1
Rome 1
Salinas 1
San Diego 1
Santa Marta 1
Sebokeng 1
Secaucus 1
South Burlington 1
Syracuse 1
Totale 1.247
Nome #
802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with nivolumab: The multicentric retrospective Meet-URO 18 study 153
Burning Questions in the Oncofertility Counseling of Young Breast Cancer Patients 152
Feasibility of multiple immunoexpression assay for immune tumor micrornvironment (I-TME) on matched metastatic and primary renal cell carcinoma (RCC) for patient prognostication and predictiveness to immunotherapy (preliminary analyses of the Meet URO 18 study). 118
597P Endometrial carcinoma and mismatch repair deficiency: Clinical association and universal screening for Lynch syndrome 116
Analyses of tumor microenvironment in patients with advanced renal cell carcinoma receiving immunotherapy (Meet-URO 18 study) 105
Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment 105
Characterization of Tumor and Immune Tumor Microenvironment of Primary Tumors and Metastatic Sites in Advanced Renal Cell Carcinoma Patients Based on Response to Nivolumab Immunotherapy: Preliminary Results from the Meet-URO 18 Study 104
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 92
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study 90
Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment 85
Moving trastuzumab emtansine (T-DM1) to the early setting of breast cancer treatment 80
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study 79
Combined response of advanced cutaneous squamous cell carcinoma and renal cell carcinoma to immunotherapy: a case report 78
Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9) 61
Totale 1.418
Categoria #
all - tutte 6.030
article - articoli 6.030
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.060


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202114 0 0 0 0 0 0 0 0 0 0 0 14
2021/202256 0 0 0 6 0 3 11 16 2 5 3 10
2022/2023147 8 10 1 14 25 17 0 18 24 6 21 3
2023/2024165 9 14 5 15 6 26 7 6 8 12 9 48
2024/2025358 29 20 6 18 24 30 25 79 22 14 51 40
2025/2026629 82 48 44 65 74 28 68 26 76 64 34 20
Totale 1.418